Inactive Instrument

Other languages Intrexon Corp Nyse

Equities

US46122T1025

Other languages

Unlock all the news: Be the first to know and act before the market!

Precigen Share Rise After Recurrent Respiratory Papillomatosis Study Shows 51% of Patients Surgery Free	03/06
Precigen, Inc. Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More Than Half of Patients Achieved Complete Response	03/06
Precigen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy	24/04
Precigen Shares Fall After Downgrade From JPMorgan	23/03
Precigen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
Precigen's Investigational RRP Therapy Gets Orphan Drug Designation in Europe	17/01
Precigen, Inc. Receives Orphan Drug Designation for PRGN- 2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission	16/01
Precigen Q3 Net Loss Widens, Revenue Falls	10/11
Precigen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11
Insider Buy: Precigen	17/23/17
Insider Buy: Precigen	16/23/16
Precigen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/23/09
Precigen, Inc Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval	09/23/09
Precigen Gets US FDA Grants Breakthrough Therapy Designation to PRGN-2012 for Recurrent Respiratory Papillomatosis Treatment	20/23/20
Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerseâ„¢ Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis	20/23/20
Precigen Unveils Positive Phase 1 Data From Advanced Stage Platinum Resistant Ovarian Cancer Patients	06/23/06
Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients	06/23/06
Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers	03/23/03
Sector Update: Health Care Stocks Advancing Late Wednesday	01/23/01

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Intrexon Corp Nyse

Equities

US46122T1025

Other languages

Filters